Chronic myeloid leukemia

CML arises from a blood-forming cell with the BCR::ABL1 fusion, usually associated with the Philadelphia chromosome. This acquired change is generally not inherited by children. Blood testing, marrow morphology and chromosome analysis establish the diagnosis and detect additional abnormalities; identifying the transcript at baseline supports future monitoring.

Chronic phase and blast phase must be distinguished. WHO's current framework treats CML as biphasic, while other systems retain accelerated-phase criteria. A report using “accelerated phase” should therefore specify the classification and findings. Rising blasts, additional chromosome abnormalities and loss of response require prompt specialist reassessment regardless of terminology.

First-line choices include imatinib and other appropriate TKIs, with availability varying by country. Faster molecular response, tolerability, other illnesses, pregnancy plans, cost and the possibility of future treatment-free remission all matter. A newer drug is not automatically the best fit for every patient.

Asciminib binds the ABL myristoyl pocket and has a current US indication for newly diagnosed adult chronic-phase Ph-positive CML, alongside other specified uses. ASC4FIRST randomized evidence includes the published 96-week analysis and a 144-week conference update, supporting deeper molecular responses than the investigator-selected comparison overall. These molecular results should not be presented as proof of a long-term survival advantage over every individual TKI.

Typical early benchmarks include BCR::ABL1 IS at or below 10% at three months, 1% at six months and 0.1% at twelve months. Current guidance interprets the trend, confirmation, treatment interruptions and individual circumstances before changing therapy; a single borderline result is not the whole decision.

Atypical transcripts may need a personalized assay and cannot always be reported on the usual IS. “Undetectable” is meaningful only with an adequate sample and stated sensitivity. Use serial results from a consistent, quality-controlled laboratory whenever possible.

Before declaring resistance, review missed doses, treatment holds, food instructions, interactions and test reliability. A confirmed molecular rise or inadequate response may warrant marrow/cytogenetic assessment and BCR::ABL1 kinase-domain mutation testing. Side-effect-driven intolerance and true resistance require different choices.

T315I and compound mutations can restrict drug options. Ponatinib and asciminib have defined roles in selected resistant disease, but their indications, dosing, cardiovascular risks and mutation sensitivities differ. Mutation results should be interpreted by the treating team rather than used as a simple online drug-matching list.

Olverembatinib is approved in China for specified CML populations, including resistant/intolerant chronic-phase disease and defined T315I-positive settings. Its evidence includes a phase Ib dose-randomized study after multiple TKIs, including some patients previously treated with ponatinib or asciminib. Dose randomization is not a head-to-head demonstration of superiority over those drugs.

After repeated resistance, seek review before progression narrows the options. A clinical trial, an alternative molecular strategy or allogeneic transplantation may be considered. Published activity and Chinese approval do not automatically establish authorization or supply in the patient's home country.

A supervised stopping attempt is reserved for selected patients in chronic phase with sufficient TKI exposure, sustained deep molecular response and access to frequent, high-quality molecular testing with rapid results. Prior disease history and the reliability of monitoring matter as much as the latest low PCR value.

EURO-SKI confirms that durable treatment-free remission is possible for a proportion of well-selected patients, while many need treatment restarted. Monitoring is especially close early and continues long term because late molecular recurrence can occur. Loss of MMR generally triggers prompt restart; do not wait for symptoms or abnormal blood counts.

Blast-phase CML is an urgent, high-risk situation. The blast lineage—myeloid or lymphoid—affects the chemotherapy or immunotherapy backbone combined with an appropriate TKI. It should not be treated as uncomplicated chronic-phase CML with a routine tablet switch.

The aim is often to regain disease control and proceed to allogeneic transplantation when feasible. Transplant decisions consider response, mutations, organ function, donor options and infection. After transplant, molecular monitoring and selected TKI or donor-lymphocyte strategies may be relevant; the plan is individualized.

TKI safety profiles differ. Pleural or pulmonary problems, vascular disease, metabolic changes, liver abnormalities, pancreatic toxicity and persistent fatigue may influence selection or dose adjustment. Report symptoms early rather than quietly skipping tablets; dose reduction in a stable responder requires a monitoring plan.

Plan pregnancy with hematology and obstetric specialists before changing treatment. Maternal TKI exposure, interruption timing, possible interferon use and breastfeeding require individualized advice; accidental pregnancy warrants prompt review. Children need pediatric expertise and monitoring of growth, bone health and development, not simple transfer of adult recommendations.

Bring the original marrow and chromosome reports, transcript type, all dated BCR::ABL1 results with units and laboratory names, mutation tests, TKI doses and interruptions, reasons for each switch and relevant heart/lung history. A graph of molecular results is often more useful than one recent report.

Clarify whether the decision concerns tolerability, a missed milestone, resistance, pregnancy, stopping treatment or transplantation. For care across countries, arrange compatible testing, a dependable prescription supply and a named team responsible for acting on rising results.